欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号SE/H/0171/001
药品名称Hemosol B0
活性成分
    • [No Active-Substance specified] 0.0 -
剂型Solution for haemodialysis/haemofiltration
上市许可持有人Baxter Holding B.V. Netherlands
参考成员国 - 产品名称Sweden (SE)
互认成员国 - 产品名称
    • Luxembourg (LU)
    • Iceland (IS)
    • Norway (NO)
    • Poland (PL)
    • Latvia (LV)
      Hemosol B0 šķīdums hemofiltrācijai un hemodialīzei
    • Lithuania (LT)
      Hemososl B0 hemodializės/hemofiltracijos tirpalas
    • Estonia (EE)
      HEMOSOL B0
    • Bulgaria (BG)
      Hemosol
    • Cyprus (CY)
      HEMOSOL B0 SOLUTION FOR HAEMOFILTRATION
    • Czechia (CZ)
      Hemosol B0
    • Slovakia (SK)
      Hemosol BO
    • Malta (MT)
    • Germany (DE)
      Hemosol B0
    • Slovenia (SI)
    • Denmark (DK)
    • Belgium (BE)
    • United Kingdom (Northern Ireland) (XI)
      Hemosol B0
    • Ireland (IE)
    • Austria (AT)
      Hemosol BO Lösung für Hämofiltration und Hämodialyse
    • France (FR)
      Hemosol
    • Spain (ES)
    • Greece (GR)
    • Finland (FI)
      Hemosol B0
    • Portugal (PT)
    • Croatia (HR)
    • Netherlands (NL)
许可日期1999/05/04
最近更新日期2024/06/19
药物ATC编码
    • B05ZB Hemofiltrates
申请类型
  • TypeLevel1：Known Active Substance
  • TypeLevel2：Initial Application
  • TypeLevel3：Bibliographic Article 4.8 (a) (ii)
  • TypeLevel4：Chemical Substance
  • TypeLevel5：Prescription Only
附件文件下载
市场状态Positive
©2006-2024 Drugfuture->European Union HMA Authorisation of Medicines DataBase